Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
by Zacks Equity Research
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Merck Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merck has been struggling lately, but the selling pressure may be coming to an end soon.
Merck (MRK) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data
by Zacks Equity Research
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Seattle Genetics Up on Positive Data From Bladder Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
by Zacks Equity Research
IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Medicines Company's Inclisiran Succeeds in Pivotal Studies
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
by Zacks Equity Research
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Here's Why AstraZeneca (AZN) is Outperforming Its Industry
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
The Zacks Analyst Blog Highlights: Procter & Gamble, Visa, United Technologies, Walmart and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Visa, United Technologies, Walmart and Merck
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
by Zacks Equity Research
BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose
by Zacks Equity Research
Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.
5 Top Dow Stocks to Buy on the Dip for a Stronger Portfolio
by Nalak Das
A fundamentally stable U.S. economy, which is growing for history setting 11 years, albeit at a slow pace and a dovish Fed in 2019 are the two major drivers of the Dow.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.63, moving -0.87% from the previous trading session.
Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
by Zacks Equity Research
Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
by Zacks Equity Research
Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.